This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hayslip, J. Articles by Fenning, R. Search for Related Content PubMed PubMed Citation Articles by Hayslip, J. Articles by Fenning, R.

Lymphoma

Safe Administration of Iodine-131 Tositumomab After Repeated Infusion-Related Reactions to Rituximab

Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA

Key Words. Follicular lymphoma • Antibodies • Monoclonal • Radioimmunotherapy • Adverse effects

Correspondence: John Hayslip, M.D., 96 Jonathan Lucas Street, CSB 903, PO Box 250635, Charleston, South Carolina 29425, USA. Telephone: 843-792-4271; Fax: 843-792-0644; e-mail: hayslip{at}musc.edu

Infusion-related reactions during administration of monoclonal antibody therapy are often mild and unlikely to recur with subsequent treatment. If patients experience another severe reaction upon reattempting treatment, future treatments with the same agent are typically not pursued. It is unclear whether different monoclonal antibodies that bind the same tumor cell or antigen are likely to induce similar infusion reactions. Here, we report the case of a patient with repeated severe infusion reactions with rituximab who subsequently safely received treatment with iodine-131 tositumomab and discuss the relevant literature.

Disclosure of potential conflicts of interest is found at the end of this article.